You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 627 The DLL3-targeted half-life extended bispecific T cell engager (HLE BiTE®) immune-oncology therapy AMG 757 has potent antitumor activity in neuroendocrine cancer

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Immuno-conjugates and chimeric molecules
627 The DLL3-targeted half-life extended bispecific T cell engager (HLE BiTE®) immune-oncology therapy AMG 757 has potent antitumor activity in neuroendocrine cancer

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020214032
Dec 20202007
Jan 20213404
Feb 202130013
Mar 202168019
Apr 202132011
May 20218014
Jun 20210024
Jul 20210014
Aug 20210019
Sep 20210015
Oct 202138025
Nov 202160024
Dec 20212206
Jan 202228030
Feb 202234023
Mar 202280028
Apr 202258018
May 20223806
Jun 202262011
Jul 20227206
Aug 202252016
Sep 20223006
Oct 20224204
Nov 202260012
Dec 20223002
Jan 20236408
Feb 20234806
Mar 202346015
Apr 202336019
May 202328015
Jun 20235006
Jul 20233006
Aug 202330013
Sep 20233406
Oct 202332018
Nov 202348014
Dec 202350013
Jan 20243600
Feb 20242605
Mar 20243809
Apr 20243007
May 202446013
Jun 202463015
Jul 202452019
Aug 20243007
Sep 202468012
Oct 202486021
Nov 202460017
Dec 202450018
Jan 202568022
Feb 202544022
Mar 20250014
Apr 20250012
May 20250014
Jun 2025102
Total23060757